Back to Search
Start Over
In Vivo Quantification of ERβ Expression by Pharmacokinetic Modeling: Studies with 18 F-FHNP PET.
In Vivo Quantification of ERβ Expression by Pharmacokinetic Modeling: Studies with 18 F-FHNP PET.
- Source :
-
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2017 Nov; Vol. 58 (11), pp. 1743-1748. Date of Electronic Publication: 2017 Jul 13. - Publication Year :
- 2017
-
Abstract
- The estrogen receptor (ER) is a target for endocrine therapy in breast cancer patients. Individual quantification of ERα and ERβ expression, rather than total ER levels, might enable better prediction of the response to treatment. We recently developed the tracer 2- <superscript>18</superscript> F-fluoro-6-(6-hydroxynaphthalen-2-yl)pyridin-3-ol ( <superscript>18</superscript> F-FHNP) for assessment of ERβ levels with PET. In the current study, we investigated several pharmacokinetic analysis methods to quantify changes in ERβ availability with <superscript>18</superscript> F-FHNP PET. Methods: Male nude rats were subcutaneously inoculated in the shoulder with ERα/ERβ-expressing SKOV3 human ovarian cancer cells. Two weeks after tumor inoculation, a dynamic <superscript>18</superscript> F-FHNP PET scan with arterial blood sampling was acquired from rats treated with vehicle or various concentrations of estradiol (nonspecific ER agonist) or genistein (ERβ-selective agonist). Different pharmacokinetic models were applied to quantify ERβ availability in the tumor. Results: Irreversible-uptake compartmental models fitted the kinetics of <superscript>18</superscript> F-FHNP uptake better than reversible models. The irreversible 3-tissue-compartment model, which included both the parent and the metabolite input function, gave results comparable to those of the irreversible 2-tissue-compartment model with only a parent input function, indicating that radioactive metabolites contributed little to the tumor uptake. Patlak graphical analysis gave metabolic rates ( K <subscript>i</subscript> , the irreversible uptake rate constant) comparable to compartment modeling. The K <subscript>i</subscript> values correlated well with ERβ expression but not with ERα, confirming that K <subscript>i</subscript> is a suitable parameter to quantify ERβ expression. SUVs at 60 min after tracer injection also correlated ( r <superscript>2</superscript> = 0.47; P = 0.04) with ERβ expression. A reduction in <superscript>18</superscript> F-FHNP tumor uptake and K <subscript>i</subscript> values was observed in the presence of estradiol or genistein. Conclusion: <superscript>18</superscript> F-FHNP PET enables assessment of ERβ availability in tumor-bearing rats. The most suitable parameter to quantify ERβ expression is the K <subscript>i</subscript> However, a simplified static imaging protocol for determining the SUVs can be applied to assess ERβ levels.<br /> (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)
- Subjects :
- Animals
Cell Line, Tumor
Estradiol pharmacokinetics
Estrogen Receptor beta agonists
Estrogen Receptor beta genetics
Female
Genistein pharmacokinetics
Humans
Image Processing, Computer-Assisted
Male
Models, Statistical
Ovarian Neoplasms diagnostic imaging
Rats
Rats, Nude
Reproducibility of Results
Estrogen Receptor beta biosynthesis
Naphthols pharmacokinetics
Positron-Emission Tomography methods
Pyridines pharmacokinetics
Radiopharmaceuticals pharmacokinetics
Subjects
Details
- Language :
- English
- ISSN :
- 1535-5667
- Volume :
- 58
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 28705918
- Full Text :
- https://doi.org/10.2967/jnumed.117.192666